Nautilus Biotechnology (NAUT) Share-based Compensation (2020 - 2026)

Nautilus Biotechnology has disclosed Share-based Compensation across 7 years of filings, most recently posting $1.4 million for Q1 2026.

• Share-based Compensation for Q1 2026 came in at $1.4 million, down 37.18% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.0 million (down 48.63% YoY), and the FY2025 annual result was $6.8 million, down 46.11% from the prior year.
• Share-based Compensation came in at $1.4 million for Q1 2026 at Nautilus Biotechnology, down from $1.5 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $3.3 million in Q2 2024 to a low of $1.4 million in Q1 2026.
• The 5-year median for Share-based Compensation is $2.9 million (2023), against an average of $2.6 million.
• Across the five-year window, Share-based Compensation soared 57.93% in 2022 and sank 53.02% in 2025, its largest moves.
• Nautilus Biotechnology's Share-based Compensation stood at $2.8 million in 2022, then gained by 8.47% to $3.1 million in 2023, then gained by 1.66% to $3.1 million in 2024, then slumped by 52.91% to $1.5 million in 2025, then retreated by 7.41% to $1.4 million in 2026.
• The last three Share-based Compensation figures came in at $1.4 million (Q1 2026), $1.5 million (Q4 2025), and $1.5 million (Q3 2025), per Business Quant data.